These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1908 related items for PubMed ID: 26452030

  • 1. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.
    Oncotarget; 2015 Nov 10; 6(35):37269-80. PubMed ID: 26452030
    [Abstract] [Full Text] [Related]

  • 2. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
    Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, Sun L, Connarn JN, Chen CS, Zhang N, Wicha MS, Sun D.
    Sci Rep; 2015 Nov 02; 5():15821. PubMed ID: 26522776
    [Abstract] [Full Text] [Related]

  • 3. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2017 Nov 02; 166(1):55-68. PubMed ID: 28702892
    [Abstract] [Full Text] [Related]

  • 4. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K, Iwatsuki M, Watanabe M, Ida S, Ishimoto T, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Baba H.
    Ann Surg Oncol; 2014 Jan 02; 21(1):343-50. PubMed ID: 24154840
    [Abstract] [Full Text] [Related]

  • 5. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.
    BMC Cancer; 2014 Nov 24; 14():869. PubMed ID: 25417825
    [Abstract] [Full Text] [Related]

  • 6. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.
    Breast Cancer Res; 2017 Jul 27; 19(1):87. PubMed ID: 28750640
    [Abstract] [Full Text] [Related]

  • 7. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.
    Gastroenterology; 2017 Jul 27; 153(1):63-76.e14. PubMed ID: 28286209
    [Abstract] [Full Text] [Related]

  • 8. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L, Burnett J, Gasparyan M, Xu F, Jiang H, Lin CC, Myers I, Korkaya H, Liu Y, Connarn J, He H, Zhang N, Wicha MS, Sun D.
    Oncotarget; 2016 Aug 09; 7(32):51408-51422. PubMed ID: 27285982
    [Abstract] [Full Text] [Related]

  • 9. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y, Liu Y, Du Y, Yin W, Lu J.
    Curr Med Res Opin; 2013 Jun 09; 29(6):633-42. PubMed ID: 23574264
    [Abstract] [Full Text] [Related]

  • 10. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
    Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ.
    Oncotarget; 2015 May 10; 6(13):11652-63. PubMed ID: 25871474
    [Abstract] [Full Text] [Related]

  • 11. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E.
    Breast Cancer Res; 2021 Mar 30; 23(1):42. PubMed ID: 33785053
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ, Chen S.
    Breast Cancer Res Treat; 2015 Jul 30; 152(1):29-39. PubMed ID: 26026468
    [Abstract] [Full Text] [Related]

  • 13. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.
    Cancer Cell; 2007 Oct 30; 12(4):395-402. PubMed ID: 17936563
    [Abstract] [Full Text] [Related]

  • 14. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov 30; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 15. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S.
    J BUON; 2013 Nov 30; 18(1):44-50. PubMed ID: 23613387
    [Abstract] [Full Text] [Related]

  • 16. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P.
    Oncologist; 2015 Sep 30; 20(9):1001-10. PubMed ID: 26245675
    [Abstract] [Full Text] [Related]

  • 17. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.
    J BUON; 2013 Sep 30; 18(1):4-16. PubMed ID: 23613383
    [Abstract] [Full Text] [Related]

  • 18. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Sep 30; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 19. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
    Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E.
    J Biol Chem; 2011 May 27; 286(21):19127-37. PubMed ID: 21471222
    [Abstract] [Full Text] [Related]

  • 20. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
    Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.
    J Clin Oncol; 2011 Jan 10; 29(2):166-73. PubMed ID: 21135276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.